Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform
PR95030
NEW YORK, March 17, 2022 /PRNewswire=KYODO JBN/ --
Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to
the development of transformational therapeutics and technologies for
neurological and psychiatric diseases, has entered into an agreement with
Columbia University ("Columbia") and the Research Foundation for Mental Hygiene
("RFMH"), to obtain worldwide exclusive rights to develop and commercialize
Columbia's proprietary CNS biomarker software platform and patent portfolio.
Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg
The foundational algorithms were initially developed by a team of Columbia
physicians, neuroscientists, and software engineers, led by Guillermo Horga,
MD, PhD, and Clifford Cassidy, PhD. This novel technology has already
demonstrated promising clinical applications in several studies across a number
of indications including schizophrenia, Parkinson's disease, Alzheimer's
disease, major depression, drug addiction, and post-traumatic stress disorder
(PTSD).
On the back of this data, Terran is further developing the algorithms by
incorporating them into Terran's cloud-based software as a medical device
(SaMD) platform. Terran is also sponsoring additional clinical research studies
at RFMH and Columbia, and is expanding the dataset, indications of interest,
and patent portfolio. Terran aims to bring forward this platform to help enable
non-invasive and cost-effective solutions for patients suffering from
neurological and psychiatric disorders.
Dr. Sam Clark, Terran's CEO, commented "The team at Columbia and RFMH has done
an incredible amount of work in building out this software platform to help
solve very difficult questions around the identification and measurement of key
brain biomarkers in neuropsychiatry. We are looking forward to continuing this
research collaboration to further this work and broaden the access to this
powerful technology."
Dr. Guillermo Horga, Associate Professor of Clinical Psychiatry at Columbia
University Vagelos College of Physicians and Surgeons, stated, "We are excited
to continue the collaboration with the Terran team to push this work even
further and explore its capabilities across a number of different disease
states and applications."
About Terran Biosciences, Inc.
Terran is a biotech platform company developing a portfolio of therapeutics and
technologies for patients with neurological and psychiatric diseases. Backed by
a number of life-science and tech investors, Terran has built a CNS-focused,
tech-enabled drug development platform, and is rapidly advancing of number of
late-stage assets, which include novel psychedelic-based therapeutics.
Terran Contact
Investor Relations:
ir@terranbiosciences.com
Media:
info@terranbiosciences.com
SOURCE Terran Biosciences, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。